End-of-day quote
Other stock markets
|
||
- USD | - |
05-23 | Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM | |
05-09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Sales 2024 * | 31.25M 42.76M | Sales 2025 * | 25M 34.21M | Capitalization | 523M 716M |
---|---|---|---|---|---|
Net income 2024 * | -59M -80.73M | Net income 2025 * | -142M -194M | EV / Sales 2024 * | 14.7 x |
Net cash position 2024 * | 63.88M 87.42M | Net cash position 2025 * | 257M 351M | EV / Sales 2025 * | 10.7 x |
P/E ratio 2024 * |
-8.77
x | P/E ratio 2025 * |
-5.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 18-11-29 |
Director of Finance/CFO | 66 | 21-12-30 | |
Anthony Blandin
CMP | Compliance Officer | - | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 10-03-31 |
Mack Gill
BRD | Director/Board Member | 72 | 04-07-31 |
Philip Hodges
BRD | Director/Board Member | 56 | 03-08-31 |
1st Jan change | Capi. | |
---|---|---|
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.47% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |